Regulating AI in Healthcare: Challenges and Opportunities

Maya Sandalow, associate director for the Bipartisan Policy Center’s health program, highlights the complexities of regulating AI tools in healthcare. The regulatory landscape varies based on AI applications and the federal agency involved. For instance, the Food and Drug Administration (FDA) regulates AI used as medical devices, focusing on safety and effectiveness. However, many AI applications, such as those for scheduling and claims processing, are not classified as medical devices, resulting in regulatory ambiguities.

The Center for Medicare and Medicaid Services plays a role in coverage and reimbursement decisions related to AI in clinical care. Simultaneously, the Office of Civil Rights at Health and Human Services (HHS) oversees patient privacy regulations under HIPAA, which is crucial when AI is integrated into traditional healthcare delivery. Devices like wearable fitness trackers may not fall under these regulations, complicating oversight. Additionally, the Federal Trade Commission may investigate misleading marketing practices of AI tools, while the Office of the National Coordinator for Health IT handles AI integration into electronic health records.

The report from the Bipartisan Policy Center emphasizes how state-level initiatives add complexity to the regulatory landscape. States enacting diverse regulations impact developers deploying AI tools across borders. Sandalow noted the challenge of aligning incentives for industry participants and crafting a unified federal regulatory framework amidst rapid AI advancements.

Sandalow discussed liability intricacies in AI utilization, mentioning ongoing policy debates, such as the model card approach by the Office of the National Coordinator for Health IT, which enhances AI tools' transparency. Concerns arise over potentially increased liability for providers if this initiative is rolled back under the new administration, leaving them without adequate guidance.

The conversation also explored the transformative potential of AI in healthcare, particularly in disease prevention and accurate diagnosis, against the backdrop of regulatory uncertainty that may stifle innovation. A federal framework appears necessary to minimize regulatory divergences across states, although consensus on specific measures remains difficult to achieve.

As AI continues to evolve, stakeholders within the insurance and healthcare sectors need to stay informed about regulatory changes. Active engagement in policy discussions will be crucial to facilitating the safe and effective implementation of AI technologies.